In a syngeneic NBL model, lysis of tumor cells by a monoclonal antitumor antibody directed against O-acetylated GD2 was found to rely on the presence of macrophages, and a combination with SIRPα-specific monoclonal antibody enhanced the anti-NBL activity of O-acetylated GD2-specific antibody therapy [192]. The gene discussed is SIRPA; the disease is neoplasm.